表紙
市場調査レポート

非小細胞肺癌(NSCLC)治療薬:パイプライン評価と2018年までの市場予測

Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

発行 GlobalData 商品コード 222281
出版日 ページ情報 英文 138 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
非小細胞肺癌(NSCLC)治療薬:パイプライン評価と2018年までの市場予測 Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
出版日: 2011年11月03日 ページ情報: 英文 138 Pages
概要

世界の非小細胞肺癌(NSCLC)治療薬市場は2010年に45億米ドル規模となり、今後CAGR9.7%で拡大し、2018年までに95億米ドルに達するとみられています。2012年初頭に、ALK遺伝子変異を有するNSCLC患者向けにPfizerがXalkoriを上市予定であることが、この成長予測の主な理由となっています。しかし、充実したパイプラインと患者人口の増加、安全性と有効性が確認された新薬は上市されるものの、現在上市されている製品の特許失効によって、成長が制限されています。進行癌の診断が増え、十分な有効性と安全性をもつジェネリック薬が入手可能なことから、今後市場は大きな課題に直面します。

当レポートでは、世界の非小細胞肺癌(NSCLC)治療薬市場について調査分析し、NSCLCの概要と治療法、主要各国別の市場規模と2018年までの成長予測、上市製品のプロファイル、開発パイプライン、将来の市場見通しなどをまとめ、概略以下の構成で取り上げております。

第1章 目次

第2章 イントロダクション

  • 概要
  • 疫学
  • 病因と病態生理学
  • 徴候と症状
  • 診断
    • 試験所検査
    • 画像検査
    • その他の検査
  • 病期:TNM分類
  • 治療
  • NSCLCに伴う遺伝子変異
  • レポートガイダンス

第3章 NSCLC:市場特性

  • 市場規模(2005〜2010年)
  • 市場予測(2010〜2018年)
  • 米国市場規模(2005〜2010年)
  • 米国市場予測(2010〜2018年)
  • 英国市場規模(2005〜2010年)
  • 英国市場予測(2010〜2018年)
  • ドイツ市場規模(2005〜2010年)
  • ドイツ市場予測(2010〜2018年)
  • イタリア市場規模(2005〜2010年)
  • イタリア市場予測(2010〜2018年)
  • フランス市場規模(2005〜2010年)
  • フランス市場予測(2010〜2018年)
  • スペイン市場規模(2005〜2010年)
  • スペイン市場予測(2010〜2018年)
  • 日本市場規模(2005〜2010年)
  • 日本市場予測(2010〜2018年)
  • 促進因子と障壁
  • 機会とアンメットニーズ
  • 要点

第4章 競合評価

  • 概要
    • 戦略的競合評価
  • 上市製品の市場プロファイル
    • Alimta
    • Avastin
    • Gemzar
    • Iressa
    • Tarceva
    • Taxotere
    • Xalkori
  • 要点

第5章 パイプライン評価

  • 概要
  • 戦略的パイプライン評価
  • 開発段階別パイプライン
  • 作用機序
  • 技術動向分析枠組み
  • 臨床開発中の有望薬剤
  • 臨床開発中の有望薬剤に関する分子プロファイル
  • 要点

第6章 治験マッピング

  • 地域別
  • 段階別
  • 治験動向別
  • 治験依頼者別
  • 参入企業

第7章 将来の競合が及ぼす影響

  • 将来的市場に影響を及ぼす主なイベント
  • 将来の市場競合シナリオ

第8章 将来の市場参入企業

第9章 ライセンシングと提携契約

第10章 付録

図表

目次
Product Code: GDHC370PRT

Summary

GlobalData, the industry analysis specialist, has released its new report, "Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Non - Small Cell Lung Cancer (NSCLC)Therapeutics market. The report identifies the key trends shaping and driving the global Non - Small Cell Lung Cancer (NSCLC)Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Non - Small Cell Lung Cancer (NSCLC)Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts

Scope

The report provides information on the key drivers and challenges of the Non - Small Cell Lung Cancer (NSCLC)Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Non - Small Cell Lung Cancer (NSCLC)Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Non - Small Cell Lung Cancer (NSCLC)Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Non - Small Cell Lung Cancer (NSCLC)Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Non - Small Cell Lung Cancer (NSCLC)Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Non - Small Cell Lung Cancer (NSCLC)Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Non - Small Cell Lung Cancer (NSCLC)Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Non - Small Cell Lung Cancer (NSCLC)Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Overview
    • 2.1.1. Cellular Classification of NSCLC
  • 2.2. Epidemiology
  • 2.3. Etiology and Pathophysiology
  • 2.4. Signs and Symptoms
  • 2.5. Diagnosis
    • 2.5.1. Laboratory Tests
    • 2.5.2. Imaging Tests
    • 2.5.3. Other Tests
  • 2.6. Staging: Tumor, Node and Metastasis (TNM) Classification
  • 2.7. Treatment
  • 2.8. Genetic Mutations Associated with NSCLC
    • 2.8.1. EGFR Mutations
    • 2.8.2. KRAS Mutations
    • 2.8.3. ALK Mutations
  • 2.9. GlobalData Pipeline Report Guidance

3. NSCLC: Market Characterization

  • 3.1. Major Markets, Market Size (2005-2010)
  • 3.2. Major Markets, Market Forecast (2010-2018)
  • 3.3. US Market Size (2005-2010)
  • 3.4. US Market Forecast (2010-2018)
  • 3.5. UK Market Size (2005-2010)
  • 3.6. UK Market Forecast (2010-2018)
  • 3.7. Germany Market Size (2005-2010)
  • 3.8. Germany Market Forecast (2010-2018)
  • 3.9. Italy Market Size (2005-2010)
  • 3.10. Italy Market Forecast (2010-2018)
  • 3.11. France Market Size (2005-2010)
  • 3.12. France Market Forecast (2010-2018)
  • 3.13. Spain Market Size (2005-2010)
  • 3.14. Spain Market Forecast (2010-2018)
  • 3.15. Japan Market Size (2005-2010)
  • 3.16. Japan Market Forecast (2010-2018)
  • 3.17. Drivers and Barriers for NSCLC Therapeutic Market
    • 3.17.1. Drivers for NSCLC Market
    • 3.17.2. Barriers for NSCLC Market
  • 3.18. Opportunity and Unmet Need
  • 3.19. Key Takeaway

4. NSCLC Market: Competitive Assessment

  • 4.1. Overview
    • 4.1.1. Strategic Competitor Assessment
  • 4.2. NSCLC Market Profile of Marketed Products
    • 4.2.1. Alimta (pemetrexed)
    • 4.2.2. Avastin (bevacizumab)
    • 4.2.3. Gemzar (gemcitabine)
    • 4.2.4. Iressa (gefitinib)
    • 4.2.5. Tarceva (erlotinib)
    • 4.2.6. Taxotere (docetaxel)
    • 4.2.7. Xalkori (crizotinib)
  • 4.3. Key Takeaway

5. NSCLC: Pipeline Assessment

  • 5.1. Overview
  • 5.2. Strategic Pipeline Assessment
  • 5.3. NSCLC Pipeline Analysis - Pipeline by Clinical Phases of Development
    • 5.3.1. NSCLC Therapeutics - Pre-Registration Pipeline
    • 5.3.2. NSCLC Therapeutics - Phase III Clinical Pipeline
    • 5.3.3. NSCLC Therapeutics - Phase II/III Clinical Pipeline
    • 5.3.4. NSCLC Therapeutics - Phase II Clinical Pipeline
    • 5.3.5. NSCLC Therapeutics - Phase I/II Clinical Pipeline
    • 5.3.6. NSCLC Therapeutics - Phase I Clinical Pipeline
    • 5.3.7. NSCLC Therapeutics - Preclinical Pipeline
    • 5.3.8. NSCLC Therapeutics - Discovery Pipeline
  • 5.4. NSCLC Pipeline by Mechanism of Action
  • 5.5. NSCLC Technology Trends Analytical Framework
  • 5.6. NSCLC - Promising Drugs Under Clinical Development
  • 5.7. Molecule Profile for Promising Drugs under Clinical Development
    • 5.7.1. Exelbine (ANX-530)
    • 5.7.2. Erbitux (cetuximab)
    • 5.7.3. Nanoplatin (lipoplatin)
    • 5.7.4. Abraxane
    • 5.7.5. Aflibercept (VEGF Trap)
    • 5.7.6. Amrubicin
    • 5.7.7. GSK1572932A (MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI))
    • 5.7.8. Iniparib (BSI-201, SAR240550)
    • 5.7.9. Lucanix
    • 5.7.10. Motesanib (AMG 706)
    • 5.7.11. Necitumumab
    • 5.7.12. Nexavar (sorafenib)
    • 5.7.13. OGX-011 (ISIS 112989, TV-1011)
    • 5.7.14. Opaxio (CT-2103, Paclitaxel Poliglumex)
    • 5.7.15. PF-00299804
    • 5.7.16. Racotumomab
    • 5.7.17. Ramucirumab (IMC-1121B)
    • 5.7.18. Stimuvax
    • 5.7.19. Talactoferrin
    • 5.7.20. Tavocept (BNP7787)
    • 5.7.21. Telcyta (canfosfamide, TLK286)
    • 5.7.22. Tomtovok (Afatinib, BIBW 2992)
    • 5.7.23. Tivantinib
    • 5.7.24. Vargatef (BIBF 1120)
    • 5.7.25. Yervoy (ipilimumab)
  • 5.8. Key Takeaway

6. NSCLC Therapeutics - Clinical Trials Mapping

  • 6.1. Clinical Trials Mapping by Region/Country
  • 6.2. Clinical Trials Mapping by Phase
  • 6.3. Clinical Trials Mapping by Trial Status
  • 6.4. Clinical Trials Mapping by Overall Sponsors
  • 6.5. Clinical Trials Mapping by Prominent Sponsors
  • 6.6. Participants in Therapeutic Clinical Trials - Companies

7. NSCLC Therapeutics: Implications for Future Competition

  • 7.1. Key Events Impacting the Future Market
  • 7.2. Future Market Competition Scenario

8. Global NSCLC Therapeutics: Future Companies in the Market

  • 8.1. Introduction
  • 8.2. Amgen Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Business Overview
  • 8.3. Bayer AG
    • 8.3.1. Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Business Overview
  • 8.4. BioNumerik Pharmaceuticals
    • 8.4.1. Overview
    • 8.4.2. Oncology Portfolio
  • 8.5. Boehringer Ingelheim GmbH
    • 8.5.1. Overview
    • 8.5.2. Business Description
    • 8.5.3. Oncology Portfolio
  • 8.6. Bristol-Myers Squibb
    • 8.6.1. Company Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Business Description
  • 8.7. Cyclacel Pharmaceuticals Inc.
    • 8.7.1. Company Overview
  • 8.8. Daiichi Sankyo
    • 8.8.1. Overview
    • 8.8.2. Financial Overview
    • 8.8.3. Business Overview
  • 8.9. Eisai Co., Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Financial Overview
    • 8.9.3. Business Description
  • 8.10. Eli Lilly and Company
    • 8.10.1. Overview
    • 8.10.2. Business Description
    • 8.10.3. Oncology Portfolio
  • 8.11. F. Hoffmann-La Roche Ltd
    • 8.11.1. Overview
    • 8.11.2. Business Description
    • 8.11.3. Oncology Portfolio
  • 8.12. GlaxoSmithKline
    • 8.12.1. Company Overview
    • 8.12.2. Financial Performance:
    • 8.12.3. Business Description
  • 8.13. Merck & Co
    • 8.13.1. Overview
    • 8.13.2. Financial Performance
    • 8.13.3. Business Description
  • 8.14. Merck KGaA
    • 8.14.1. Company Overview
    • 8.14.2. Financial Overview
    • 8.14.3. Business Overview
  • 8.15. Novartis AG
    • 8.15.1. Company Overview
    • 8.15.2. Financial Overview
    • 8.15.3. Business Overview
  • 8.16. Pfizer Inc.
    • 8.16.1. Overview
    • 8.16.2. Business Description
  • 8.17. Sanofi-Aventis
    • 8.17.1. Company Overview
    • 8.17.2. Financial Overview
    • 8.17.3. Business Description
  • 8.18. Takeda Pharmaceutical Company Limited
    • 8.18.1. Overview
    • 8.18.2. Financial Overview
    • 8.18.3. Business Description
  • 8.19. Telik Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Financial Overview
    • 8.19.3. Business Overview

9. Licensing and Partnership Deals

10. Global NSCLC Market: Appendix

  • 10.1. Definitions
  • 10.2. Acronyms
  • 10.3. Methodology
    • 10.3.1. Coverage
    • 10.3.2. Secondary Research
    • 10.3.3. Forecasting
    • 10.3.4. Primary Research
    • 10.3.5. Expert Panel Validation
  • 10.4. Contact Us
  • 10.5. Disclaimer
  • 10.6. Sources

List of Tables

  • Table 1: Incidence and Prevalence of NSCLC in 2010
  • Table 2: NSCLC, TNM Definitions
  • Table 3: NSCLC Staging, TNM Codes
  • Table 4: Treatment Options for NSCLC
  • Table 5: Chemotherapy Regimens Used for NSCLC
  • Table 6: Commonly Used Regimens for Metastasis of NSCLC
  • Table 7: Oncogene Mutations - Prevalence and Predicted Response Rates
  • Table 8: NSCLC Therapeutics, Global, Market Revenue ($m), 2005-2010
  • Table 9: NSCLC Therapeutics, Global, Revenue Forecasts ($m), 2010-2018
  • Table 10: NSCLC Therapeutics, the US, Market Historical Revenue ($m), 2005-2010
  • Table 11: NSCLC Therapeutics, the US, Historical Revenue Forecasts ($m), 2010-2018
  • Table 12: NSCLC Therapeutics, the UK, Market Revenue ($m), 2005-2010
  • Table 13: NSCLC Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018
  • Table 14: NSCLC Therapeutics, Germany, Market Revenue ($m), 2005-2010
  • Table 15: NSCLC Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018
  • Table 16: NSCLCTherapeutics, Italy, Market Revenue ($m), 2005-2010
  • Table 17: NSCLC Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018
  • Table 18: NSCLC Therapeutics, France, Market Revenue ($m), 2005-2010
  • Table 19: NSCLC Therapeutics, France, Revenue Forecasts ($m), 2010-2018
  • Table 20: NSCLC Therapeutics, Spain, Market Revenue ($m), 2005-2010
  • Table 21: NSCLC Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018
  • Table 22: NSCLC Therapeutics, Japan, Market Revenue ($m), 2005-2010
  • Table 23: NSCLC Therapeutics, Japan, Revenue Forecasts ($m), 2010-2018
  • Table 24: NSCLC Therapeutics - Pre-Registration Molecules, 2011
  • Table 25: NSCLC Therapeutics - Phase III Clinical Pipeline, 2011
  • Table 26: NSCLC Therapeutics - Phase II/III Clinical Pipeline, 2011
  • Table 27: NSCLC Therapeutics - Phase II Clinical Pipeline, 2011
  • Table 28: NSCLC Therapeutics - Phase I/II Clinical Pipeline, 2011
  • Table 29: NSCLC Therapeutics - Phase I Clinical Pipeline, 2011
  • Table 30: NSCLC Therapeutics - Preclinical Pipeline, 2011
  • Table 31: NSCLC Therapeutics - Discovery Pipeline, 2011
  • Table 32: Mechanisms of Action that Constitute Classes in Figure 28
  • Table 33: NSCLC Therapeutics - Promising Drugs Under Clinical Development, 2011
  • Table 34: NSCLC Clinical Trials by Region - Number, 2011
  • Table 35: NSCLC Clinical Trials by Phase, 2011
  • Table 36: NSCLC Clinical Trials by Status, 2011
  • Table 37: NSCLC Clinical Trials by Overall Sponsors, 2011
  • Table 38: NSCLC Clinical Trials by Prominent Sponsors, 2011
  • Table 39: NSCLC Therapeutic Clinical Trial - Company Sponsors by Phase, 2011
  • Table 40: Amgen - Promising Molecules in Pipeline for Oncology, 2011
  • Table 41: Bayer - Promising Molecules in Pipeline for Oncology, 2011
  • Table 42: BioNumerik Pharmaceuticals, Inc. - Oncology Pipeline Products, 2011
  • Table 43: BioNumerik Pharmaceuticals, Inc. - NSCLC Pipeline Products, 2011
  • Table 44: Boehringer Ingelheim GmbH - Oncology Pipeline, 2011
  • Table 45: BMS - Promising Molecules in Pipeline for Oncology, 2011
  • Table 46: Cyclacel Pharma - Promising Molecules in Pipeline for Oncology, 2011
  • Table 47: Daiichi Sankyo - Promising Molecules in Pipeline for Oncology, 2011
  • Table 48: Eisai - Oncology Pipeline, 2011
  • Table 49: Eli Lilly, Oncology Pipeline, 2011
  • Table 50: F. Hoffmann-La Roche Ltd, Oncology Pipeline, 2011
  • Table 51: GSK - Oncology Pipeline, 2011
  • Table 52: Merck - Oncology Pipeline, 2011
  • Table 53: Merck Sorono - Oncology Pipeline, 2010
  • Table 54: Novartis - Oncology Pipeline, 2010
  • Table 55: Pfizer - Oncology Pipeline, 2010
  • Table 56: Sanofi-Aventis - Promising Molecules in Pipeline for Oncology, 2011
  • Table 57: Telik - Promising Molecules in Pipeline for Oncology, 2011
  • Table 58: NSCLC Therapeutics, Licensing and Partnership Deals

List of Figures

  • Figure 1: NSCLC Therapeutics, Global, Market Revenue ($m), 2005-2010
  • Figure 2: NSCLC Therapeutics, Market Share ($m), 2010
  • Figure 3: NSCLC Therapeutics, Global, Revenue Forecasts ($m), 2010-2018
  • Figure 4: NSCLC Therapeutics, Forecast Market Share ($m), 2018
  • Figure 5: NSCLC Therapeutics, the US, Market Revenue ($m), 2005-2010
  • Figure 6: NSCLC Therapeutics, the US, Revenue Forecasts ($m), 2010-2018
  • Figure 7: NSCLC Therapeutics, the UK, Market Revenue ($m), 2005-2010
  • Figure 8: NSCLC Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018
  • Figure 9: NSCLC Therapeutics, Germany, Market Revenue ($m), 2005-2010
  • Figure 10: NSCLC Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018
  • Figure 11: NSCLC Therapeutics, Italy, Market Revenue ($m), 2005-2010
  • Figure 12: NSCLC Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018
  • Figure 13: NSCLC Therapeutics, France, Market Revenue ($m), 2005-2010
  • Figure 14: NSCLC Therapeutics, France, Revenue Forecasts ($m), 2010-2018
  • Figure 15: NSCLC Therapeutics, Spain, Market Revenue ($m), 2005-2010
  • Figure 16: NSCLC Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018
  • Figure 17: NSCLC Therapeutics, Japan, Market Revenue ($m), 2005-2010
  • Figure 18: NSCLC Therapeutics, Japan, Revenue Forecasts ($m), 2010-2018
  • Figure 19: Opportunity and Unmet Need in the NSCLC Therapeutic Market - Overall
  • Figure 20:Opportunity and Unmet Need in the NSCLC Therapeutic Market - First-Line Treatment
  • Figure 21: Opportunity and Unmet Need in the NSCLC Therapeutic Market - Second-Line Treatment
  • Figure 22: Opportunity and Unmet Need in the NSCLC Therapeutic Market - Maintenance Therapy
  • Figure 23: Strategic Competitor Assessment of Marketed Products for NSCLC, 2010
  • Figure 24: Pipeline Products by Phase of Clinical Development, 2011
  • Figure 25: NSCLC Therapeutics Pipeline by Phase of Clinical Development, 2011
  • Figure 26: NSCLC Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011
  • Figure 27: Technology Trends Analytical Framework of the NSCLC Pipeline, 2011
  • Figure 28: Technology Trends Analytical Framework of the NSCLC Pipeline - Description, 2011
  • Figure 29: NSCLC Clinical Trials by Region, 2011
  • Figure 30: NSCLC Clinical Trials by Phase, 2011
  • Figure 31: NSCLC Clinical Trials by Status, 2011
  • Figure 32: NSCLC Clinical Trials by Sponsors, 2011
  • Figure 33: NSCLC Clinical Trials by Prominent Sponsors, 2011
  • Figure 34: NSCLC Therapeutic Clinical Trial - Company Sponsors by Phase, 2011
  • Figure 35: NSCLC Therapeutics, Key Events Impacting Future Market
  • Figure 36: Implications for Future Market Competition in the NSCLC Market, 2011
  • Figure 37: NSCLC Therapeutics, Clinical Pipeline by Company, 2011
  • Figure 38: GlobalData Market Forecasting Model
Back to Top